These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy. Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093 [TBL] [Abstract][Full Text] [Related]
8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070 [TBL] [Abstract][Full Text] [Related]
9. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study. Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662 [TBL] [Abstract][Full Text] [Related]
10. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296 [TBL] [Abstract][Full Text] [Related]
11. Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study. Pellegrini C; Esposito M; Rossi E; Gisondi P; Piaserico S; Dapavo P; Conti A; Gambardella A; Burlando M; Narcisi A; Offidani A; Balestri R; Bardazzi F; Prignano F; Mugheddu C; Romanelli M; Malara G; Schinzari G; Fargnoli MC Dermatol Ther (Heidelb); 2022 Nov; 12(11):2613-2626. PubMed ID: 36169883 [TBL] [Abstract][Full Text] [Related]
12. PSSD and biologic therapy: Real-life data in 417 patients with moderate to severe psoriasis. Proietti I; Bernardini N; Skroza N; Mambrin A; Tolino E; Marchesiello A; Marraffa F; Rossi G; Volpe S; Potenza C Rev Recent Clin Trials; 2022 Jun; ():. PubMed ID: 35747967 [TBL] [Abstract][Full Text] [Related]
13. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. Zagni E; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Zullo A; Fiocchi M; Colombo D BMC Health Serv Res; 2021 Sep; 21(1):924. PubMed ID: 34488749 [TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P Sci Rep; 2022 Sep; 12(1):15078. PubMed ID: 36064563 [TBL] [Abstract][Full Text] [Related]
15. Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study. Megna M; Battista T; Noto M; Picone V; Fabbrocini G; Ruggiero A; Genco L Clin Cosmet Investig Dermatol; 2023; 16():553-564. PubMed ID: 36896374 [TBL] [Abstract][Full Text] [Related]
16. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting. Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225 [TBL] [Abstract][Full Text] [Related]
17. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis. Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Chinchay FV; Galán-Gutiérrez M Dermatol Ther; 2022 Oct; 35(10):e15760. PubMed ID: 35971573 [TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124 [TBL] [Abstract][Full Text] [Related]
19. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study. Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G Dermatol Ther; 2022 Jul; 35(7):e15524. PubMed ID: 35439341 [TBL] [Abstract][Full Text] [Related]